Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) FCF Margin (2021 - 2025)

Lyra Therapeutics has reported FCF Margin over the past 5 years, most recently at 88028.57% for Q4 2025.

  • Quarterly results put FCF Margin at 88028.57% for Q4 2025, down 8262474.0% from a year ago — trailing twelve months through Dec 2025 was 7275.13% (down 255876.0% YoY), and the annual figure for FY2025 was 7280.15%, down 256379.0%.
  • FCF Margin for Q4 2025 was 88028.57% at Lyra Therapeutics, down from 29444.0% in the prior quarter.
  • Over the last five years, FCF Margin for LYRA hit a ceiling of 1596.76% in Q2 2022 and a floor of 110836.36% in Q4 2022.
  • Median FCF Margin over the past 5 years was 4559.17% (2024), compared with a mean of 20164.65%.
  • Biggest five-year swings in FCF Margin: tumbled -10580574bps in 2022 and later surged 9736171bps in 2023.
  • Lyra Therapeutics' FCF Margin stood at 5030.63% in 2021, then plummeted by -2103bps to 110836.36% in 2022, then surged by 88bps to 13474.66% in 2023, then surged by 60bps to 5403.83% in 2024, then plummeted by -1529bps to 88028.57% in 2025.
  • The last three reported values for FCF Margin were 88028.57% (Q4 2025), 29444.0% (Q3 2025), and 3601.09% (Q2 2025) per Business Quant data.